- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06157801
Evaluation of Hereditary Cancer Educational Videos
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective
Determine the impact of educational videos on:
- Participant's hereditary cancer knowledge.
- Participant's confidence to share hereditary cancer information with family members.
Secondary Objective
- Determine impact of educational videos on participant's confidence to undergo hereditary cancer screening.
- Identify opportunities to tailor and improve the educational video's content, style, and understandability per participant preferences and feedback.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jose Rauh-Hain, MD
- Phone Number: (713) 794-1759
- Email: jarauh@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Contact:
- Jose Rauh-Hain, MD
- Phone Number: 713-794-1759
- Email: jarauh@mdanderson.org
-
Principal Investigator:
- Jose Rauh-Hain, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants of The Harris Health System Lyndon B. Johnson (LBJ) Hospital outpatient oncology clinics (i.e., Gynecologic Oncology, Medical Oncology).
- 18 years of age or older.
- Speaks and/or reads English or Spanish.
- Has a pathogenic or likely pathogenic variant (mutation) in BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, and/or EPCAM on germline genetic testing.
- Has a documented genetic testing results disclosure encounter (i.e. telephone call, follow-up appointment).
Exclusion Criteria:
- No longer receives outpatient care at LBJ Hospital at time of recruitment.
- Has only a variant of uncertain significance in BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, and/or EPCAM.
- Has only a pathogenic or likely pathogenic variant in gene other than BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, or EPCAM.
- Is unwilling, unable, or requires a legally authorized representative to provide informed consent.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Interview Study
In the interview study, participants will watch the video, then complete an interview.
This will take about 50 minutes.
|
All study participants will have the following demographic information collected from their medical records:
|
Survey Study
In the survey study, participants will complete a survey about your education and complete a quick test about your knowledge of hereditary cancer.
Participants will then watch the video.
complete another survey similar to the one before the video.
This should take about 30 minutes.
|
All study participants will have the following demographic information collected from their medical records:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hereditary Cancer Multidimensional Measure of Informed Choice Questionnaires
Time Frame: through study completion; an average of 1 year
|
Hereditary Cancer Multidimensional Measure of Informed Choice (MMIC) Knowledge Score scale: (1-8) true or false |
through study completion; an average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jose Rauh-Hain, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2023-0654
- NCI-2023-10074 (Other Identifier: NCI-CTRP Clinical Registry)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Cancer
-
University of Texas Southwestern Medical CenterRecruiting
-
Myriad Genetic Laboratories, Inc.Myriad Genetics, Inc.CompletedHereditary CancerUnited States
-
University of PennsylvaniaFox Chase Cancer CenterCompletedCardiovascular Diseases | Cancer | Hereditary Cancer | Hereditary Cardiac AmyloidosisUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Georgetown UniversityNot yet recruitingHereditary Cancer | Genetic Testing
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedHereditary Cancer | Genetic CounselingMexico
-
Pro-Change Behavior SystemsRecruitingMental Health Issue | Hereditary CancerUnited States
-
InheRET, IncUniversity of MichiganEnrolling by invitationHereditary Cancer-Predisposing SyndromeUnited States
-
Weill Medical College of Cornell UniversityRecruitingGynecologic Cancer | Hereditary Cancer SyndromeUnited States
-
Myriad Genetic Laboratories, Inc.Completed
-
Institut Claudius RegaudUnknownHereditary Breast and Ovarian Cancer | Hereditary Cancer Syndrome | Hereditary Colorectal Endometrial Cancer SyndromeFrance
Clinical Trials on Interview Study
-
Baxalta now part of ShireCompleted
-
Queen's University, BelfastUniversity of Ulster; University of Southern Denmark; Loughborough UniversityCompletedSedentary BehaviorUnited Kingdom
-
Hampshire Hospitals NHS Foundation TrustRecruitingPeritoneal Cancer | Post-Splenectomy InfectionUnited Kingdom
-
The University of Hong KongUnknownSmoking CessationHong Kong
-
Satellite HealthcareCompleted
-
King's College LondonRecruitingSurgery | Patient Satisfaction | Patient Preference | Muscle Invasive Bladder Cancer | Sexual WellbeingUnited Kingdom
-
University Hospital, CaenCompleted
-
King's College LondonCompleted
-
Cereneo AGcereneo Institute for Interdsciplinary Research (cefir)CompletedStroke | Diet Modification | RelativesSwitzerland